Lymphoma & Plasma Cell Disorders
Feature
Cancer patients report delays in treatment because of COVID-19
Half of survey respondents in active treatment reported changes, delays, or disruptions to care.
From the Journals
Cancer care ‘transformed in space of a month’ because of pandemic
Changes brought about by COVID-19 may endure after the pandemic is over.
From the Journals
Oncologists need to advocate for scarce COVID-19 resources: ASCO
The oncologist treating a patient should not make decisions about resource allocation for that patient, ASCO says.
Feature
ASCO announces its own COVID-19 and cancer registry
ASCO aims to learn how COVID-19 is impacting cancer patients’ treatment and outcomes.
From the Journals
CAR T-cell therapy effective for r/r B-cell lymphoma of the GI tract
From the Journals
Lymphocyte, monocyte data can predict treatment response in follicular lymphoma
Blood cell count values at diagnosis can predict the clinical outcomes in follicular lymphoma.
From the Journals
Cancer prevalence among COVID-19 patients may be higher than previously reported
A meta-analysis suggests the cancer prevalence among COVID-19 patients is 2%, not 1% as previously reported.
Feature
Home-based chemo skyrockets at one U.S. center
The University of Pennsylvania’s home-based chemotherapy program experienced a 300% increase in participation in a 5-week period.
From the Journals
Managing pediatric heme/onc departments during the pandemic
An international group has devised a plan for preventing the spread of infection, treating COVID-19, and adjusting cancer treatments.
Feature
Conducting cancer trials amid the COVID-19 pandemic
From the Journals
‘Brutal’ plan to restrict palliative radiation during pandemic
New guidelines recommend giving palliative radiotherapy only in oncologic emergencies during the COVID-19 pandemic.